Side effects of approved antidementives

Area of Science:

• Pharmacology and Therapeutics
• Neuroscience
• Geriatrics

Background:

• Alzheimer's disease and other dementias represent a growing public health challenge.
• Pharmacological interventions are crucial for managing cognitive decline and associated symptoms.
• Understanding the safety profiles of antidementive medications is essential for clinical practice.

Purpose of the Study:

• To comprehensively review the side effect profiles of five United States Food and Drug Administration (FDA)-approved antidementive medications.
• To differentiate the adverse events associated with acetylcholinesterase inhibitors versus memantine, a NMDA receptor antagonist.

Main Methods:

• Systematic review of literature focusing on adverse events reported for four acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine, tacrine) and memantine.
• Analysis of reported side effects, including incidence, severity, and relationship to drug class and dosage.

Main Results:

• Acetylcholinesterase inhibitors are generally well-tolerated, with gastrointestinal side effects (nausea, diarrhea, vomiting, weight loss) being most common, linked to cholinergic inhibition.
• Hepatotoxicity is a noted concern with tacrine.
• Memantine, a non-cholinesterase inhibitor, presents with generally mild and transient side effects such as constipation, dizziness, headache, and confusion.

Conclusions:

• Most FDA-approved antidementives exhibit favorable tolerability, with specific side effect patterns for each drug class.
• Gastrointestinal disturbances are characteristic of acetylcholinesterase inhibitors, while memantine's side effects are typically mild and transient.
• Careful patient monitoring and dose titration are important for managing potential adverse events, particularly with acetylcholinesterase inhibitors.